An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.
from Reuters: Science News https://ift.tt/2PK6nWN
//
Tuesday, 23 October 2018
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment